Torno Capital’s Krystal Biotech KRYS Stock Holding History

Torno Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,500	Closed	-$267K	–	275
2024 Q1	$267K	Buy	+1,500	New	+$208K	0.02%	194

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Torno Capital's KRYS Position: Q2 2024 in Review

Torno Capital sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 1,500 shares — an estimated $267K sold.

Torno Capital first reported a position in KRYS in Q1 2024 and held it in 1 quarter. The position peaked at $267K in Q1 2024. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

Torno Capital reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
Torno Capital sold 1,500 Krystal Biotech shares in Q2 2024, an estimated $267K.
Torno Capital first reported a position in Krystal Biotech in Q1 2024 and held it in 1 quarter.
Torno Capital's Krystal Biotech position peaked at $267K in Q1 2024.
245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Torno Capital's 13F filing for Q2 2024, filed 14 Aug 2024.